超重与肥胖对常染色体显性多囊肾病进展至终末期肾病的影响:早期与晚期差异
基于HALT多囊肾病试验的两项队列,研究分析BMI与ADPKD进展至ESKD的关联。早期ADPKD(研究A,N=556)中较高BMI与ESKD风险增加相关,肥胖者风险显著升高(HR 2.71);晚期ADPKD(研究B,N=483)中未观察到该关联。
要点
- 早期ADPKD患者中,较高BMI增加进展至ESKD的风险。
- 早期ADPKD肥胖患者ESKD风险较正常体重者显著升高(HR 2.71)。
- 晚期ADPKD患者中BMI与ESKD进展风险无显著关联。
核心结论
- 较高BMI尤其肥胖增加早期ADPKD患者进展至ESKD的风险,但不增加晚期ADPKD患者的风险。
研究设计与样本
- 研究A纳入早期ADPKD患者556例,平均eGFR 91±17 ml/min per 1.73 m2。
- 研究B纳入晚期ADPKD患者483例,平均eGFR 48±12 ml/min per 1.73 m2。
- 参与者来自HALT多囊肾病试验,按BMI分为正常体重、超重和肥胖三组。
- 采用Kaplan-Meier生存分析和多因素Cox比例风险模型评估BMI与ESKD风险的关联。
- 中位随访时间:研究A为12.2年,研究B为7.3年。
主要发现
- 研究A中ESKD事件数:正常体重12例,超重24例,肥胖23例。
- 研究B中ESKD事件数:正常体重89例,超重102例,肥胖92例。
- 研究A中BMI每升高1单位,ESKD风险HR为1.09(95%CI 1.03-1.15)。
- 研究B中BMI每升高1单位,ESKD风险HR为0.98(95%CI 0.96-1.00)。
- 研究A中肥胖者较正常体重者ESKD风险HR为2.71(95%CI 1.22-6.02)。
关键数值与推荐
- BMI分类标准:正常体重18.5–24.9 kg/m2,超重25.0–29.9 kg/m2,肥胖≥30 kg/m2。
- ESKD判定依据美国肾脏数据系统(USRDS)。
- 死亡作为竞争风险采用Fine and Gray方法分析。
临床怎么用
- 对早期ADPKD患者应关注体重管理,肥胖可能加速进展至ESKD。
- 晚期ADPKD患者中BMI与ESKD进展的关联不显著,体重管理策略需个体化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Higher body mass index increased risk of progression to ESKD in patients with early-stage autosomal dominant polycystic kidney disease. Higher body mass index did not increase the risk of progression to ESKD in patients with late-stage autosomal dominant polycystic kidney disease. BACKGROUND: Prior research has linked higher body mass index (BMI) and greater visceral adiposity with more rapid progression of early-stage autosomal dominant polycystic kidney disease (ADPKD). We now evaluate the association between overweight and obesity in patients with early- and late-stage ADPKD with progression to ESKD. METHODS: Participants with early-stage ADPKD (study A; N=556; eGFR: 91±17 ml/min per 1.73 m2) and late-stage ADPKD (study B; N=483; eGFR: 48±12 ml/min per 1.73 m2) who participated in the Halt Progression of Polycystic Kidney Disease (HALT) polycystic kidney disease trials were categorized by BMI as normal weight (18.5–24.9 kg/m2; ref; n=357), overweight (25.0–29.9 kg/m2; n=384), or obese (≥30 kg/m2; n=298). Kaplan–Meier survival analysis and multivariate Cox proportional hazard models were used to determine the association of baseline BMI as a continuous and categorical variable with risk of ESKD (according to the United States Renal Data System) over a median (interquartile range) follow-up period of 12.2 (7.5–13.3; study A) and 7.3 (5.1–11.7; study B) years (primary outcome). All-cause mortality (National Death Index) was also considered as a competing risk (Fine and Gray method). RESULTS: The number of ESKD events was greater with overweight (n=24) and obesity (n=23) in HALT study A versus normal weight (n=12) but not in HALT study B (normal weight: n=89, overweight: n=102, obese: n=92). In fully adjusted models, higher BMI was associated with risk of progression to ESKD in study A (hazard ratio [HR (95% confidence interval)], 1.09 [1.03 to 1.15] per unit higher BMI) but not in study B (HR, 0.98 [0.96 to 1.00]). Obesity was associated with increased risk of ESKD (HR, 2.71 [1.22 to 6.02] versus normal weight) in study A only. Results were similar when considering death as a competing risk. CONCLUSIONS: Higher BMI, particularly obesity, increased the risk of progression to ESKD in patients with early-stage ADPKD but not in those with late-stage ADPKD.
引用
- Nowak KL, Copeland TP, Ku E, et al. Overweight Status, Obesity, and Progression to ESKD in Patients with Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2025. PMID: 39970002. doi:10.2215/CJN.0000000640
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。